CMMB

Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, focused on developing groundbreaking biological therapies for inflammatory and fibrotic diseases. Its lead product candidate, CM-101, is a monoclonal antibody designed to inhibit key pathways implicated in fibrosis, showcasing potential across various therapeutic areas. With a commitment to advancing innovative solutions, Chemomab leverages its proprietary technology platform to address significant medical challenges, striving to enhance patient outcomes and quality of life in underserved populations. The company’s strategic focus on meeting critical healthcare needs positions it as a promising player in the biopharmaceutical landscape.